title: [Intrapericardial infusion of etoposide and cisplatin in treating malignant pericardial effusion of non-small cell lung cancer].
abstract: OBJECTIVE
  Pericardiocentesis and intrapericardial infusion of chemotherapeutic drugs is the main treatment of malignant pericardial effusion. This study was to observe the efficacy and side effect of intrapericardial infusion of etoposide (VP-16) and cisplatin (DDP) on malignant pericardial effusion of non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Twenty-eight NSCLC patients with malignant pericardial effusion were treated with pericardiocentesis and intrapericardial infusion of VP-16 (200-300 mg) and DDP (80-100 mg). Intravenous chemotherapy were given 2 weeks after the pericardiocentesis.
  
  
  RESULTS
  The overall response(OR) rate of the first-time treatment of the 28 patients was 85.7%, with complete response (CR) rate of 71.4%; the OR rate of the second-time treatment was 100%. Only 4 patients needed second-time pericardiocentesis. Sixteen patients developed gastrointestinal tract reaction (mainly grade I-II), 12 developed myelosuppression (mainly grade I), and 1 showed mild abnormal of transaminase. For the 24 naïve patients, the overall survival time was 14 months for stage IIIB and 10.9 months for stage IV; whereas for the 4 patients with relapsed disease, the overall survival time was 6 months (from the time of relapse).
  
  
  CONCLUSIONS
  Intrapericardial infusion of VP-16 and DDP is an effective treatment for malignant pericardial effusion of NSCLC.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China. ssnow2005@163.com
authors.forename: Li-Kun
authors.initials: LK
authors.lastname: Chen
authors.forename: Guang-Chuan
authors.initials: GC
authors.lastname: Xu
authors.forename: Ying
authors.initials: Y
authors.lastname: Liang
authors.forename: Qun-Ying
authors.initials: QY
authors.lastname: Yang
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010490:Pericardial Effusion / Q000188:drug therapy* / Q000209:etiology; D020519:Pericardiocentesis; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D002945:Cisplatin